{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:48:03Z","timestamp":1769233683108,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00277-024-05906-6","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T06:02:24Z","timestamp":1726207344000},"page":"4537-4544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib"],"prefix":"10.1007","volume":"103","author":[{"given":"Luc\u00eda","family":"P\u00e9rez-Lamas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n Segura","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira Mora","family":"Caster\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta Hidalgo","family":"Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Paz","family":"Coll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"De las Heras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montse","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia V\u00e9lez","family":"Tenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena Sierra","family":"Pacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia Senin","family":"Magan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Angona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Cervero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"de Paz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araceli Salamanca","family":"Cuenca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Santaliestra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier L\u00f3pez","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Felipe","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valent\u00edn","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"issue":"9","key":"5906_CR1","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Kantarjian H (2022) Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol 97(9):1236\u20131256. https:\/\/doi.org\/10.1002\/ajh.26642","journal-title":"Am J Hematol"},{"issue":"4","key":"5906_CR2","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"issue":"6","key":"5906_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.clml.2016.03.004","volume":"16","author":"HJ Khoury","year":"2016","unstructured":"Khoury HJ et al (2016) Cross-intolerance with Dasatinib among Imatinib-intolerant patients with chronic phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 16(6):341\u2013349. https:\/\/doi.org\/10.1016\/j.clml.2016.03.004","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5906_CR4","doi-asserted-by":"publisher","unstructured":"Cortes JE et al (2011) Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117:5600\u20135606. https:\/\/doi.org\/10.1182\/blood-2010-11-318949","DOI":"10.1182\/blood-2010-11-318949"},{"issue":"12","key":"5906_CR5","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.3324\/haematol.2022.281944","volume":"108","author":"JE Cortes","year":"2023","unstructured":"Cortes JE et al (2023) Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I\/II study. Haematologica 108(12):3454\u20133459. https:\/\/doi.org\/10.3324\/haematol.2022.281944","journal-title":"Haematologica"},{"issue":"24","key":"5906_CR6","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/nejmoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP et al (2019) Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 381(24):2315\u20132326. https:\/\/doi.org\/10.1056\/nejmoa1902328","journal-title":"N Engl J Med"},{"key":"5906_CR7","doi-asserted-by":"publisher","unstructured":"R\u00e9a D et al (2021) Nov., A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs, Blood, 138(21):2031\u20132041, https:\/\/doi.org\/10.1182\/blood.2020009984","DOI":"10.1182\/blood.2020009984"},{"key":"5906_CR8","doi-asserted-by":"publisher","unstructured":"Schoepfer J et al (2018) Sep., Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1, J. Med. Chem, 61(18):8120\u20138135, https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01040","DOI":"10.1021\/acs.jmedchem.8b01040"},{"key":"5906_CR9","doi-asserted-by":"publisher","unstructured":"R\u00e9a D, Hughes TP (2022) Development of asciminib, a novel allosteric inhibitor of BCR-ABL1, Critical Reviews in Oncology\/Hematology, 171. Elsevier Ireland Ltd, Mar. 01, https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103580","DOI":"10.1016\/j.critrevonc.2022.103580"},{"key":"5906_CR10","doi-asserted-by":"publisher","unstructured":"Luna A et al (2022) Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Ann Hematol 101(10):2263\u20132270. https:\/\/doi.org\/10.1007\/s00277-022-04932-6","DOI":"10.1007\/s00277-022-04932-6"},{"key":"5906_CR11","doi-asserted-by":"publisher","unstructured":"Manley PW, Barys L, Cowan-Jacob SW (2020) The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res 98:106458. https:\/\/doi.org\/10.1016\/j.leukres.2020.106458","DOI":"10.1016\/j.leukres.2020.106458"},{"key":"5906_CR12","doi-asserted-by":"publisher","unstructured":"P\u00e9rez-Lamas L et al (2023) Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors, Cancers (Basel), 15(4):1045, https:\/\/doi.org\/10.3390\/cancers15041045","DOI":"10.3390\/cancers15041045"},{"key":"5906_CR13","unstructured":"Neil KHB, Shah P, Bhatia R, Altman JK, Amaya M et al NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Chronic Myeloid Leukemia Version 2.2024 \u2014 December 5, 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf"},{"key":"5906_CR14","doi-asserted-by":"publisher","unstructured":"Wylie AA et al (2017) Mar., The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1, Nature, 543(7647):733\u2013737, https:\/\/doi.org\/10.1038\/nature21702","DOI":"10.1038\/nature21702"},{"key":"5906_CR15","doi-asserted-by":"publisher","unstructured":"Cortes J et al (2023) Nov., Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph\u2009+\u2009CM, Blood, 142(Supplement 1):868\u2013868, https:\/\/doi.org\/10.1182\/blood-2023-189270","DOI":"10.1182\/blood-2023-189270"},{"key":"5906_CR16","doi-asserted-by":"publisher","unstructured":"Mauro M et al (2022) Nov., Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study, Blood, 140(Supplement 1):6765\u20136766, https:\/\/doi.org\/10.1182\/blood-2022-160138","DOI":"10.1182\/blood-2022-160138"},{"key":"5906_CR17","doi-asserted-by":"publisher","unstructured":"Hughes TP et al (2023) Nov., Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study, Blood, 142(Supplement 1):866\u2013866, https:\/\/doi.org\/10.1182\/blood-2023-182100","DOI":"10.1182\/blood-2023-182100"},{"issue":"1","key":"5906_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-022-01334-z","volume":"15","author":"Q Jiang","year":"2022","unstructured":"Jiang Q et al (2022) Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial. J Hematol Oncol 15(1):1\u201316. https:\/\/doi.org\/10.1186\/s13045-022-01334-z","journal-title":"J Hematol Oncol"},{"key":"5906_CR19","doi-asserted-by":"publisher","unstructured":"Jabbour E et al (2023) Nov., Update of Olverembatinib (HQP1351) Overcoming Ponatinib and\/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated\/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph\u2009+\u2009ALL), Blood, 142(Supplement 1):1798\u20131798, https:\/\/doi.org\/10.1182\/blood-2023-187744","DOI":"10.1182\/blood-2023-187744"},{"key":"5906_CR20","doi-asserted-by":"publisher","unstructured":"Cortes JE et al (2022) Nov., Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph\u2009+\u2009CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy, Blood, 140(Supplement 1):205\u2013207, https:\/\/doi.org\/10.1182\/blood-2022-166452","DOI":"10.1182\/blood-2022-166452"},{"key":"5906_CR21","doi-asserted-by":"publisher","unstructured":"Jiang Q et al (2023) Nov., Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant\/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study, Blood, 142(Supplement 1):867\u2013867, https:\/\/doi.org\/10.1182\/blood-2023-185977","DOI":"10.1182\/blood-2023-185977"},{"key":"5906_CR22","doi-asserted-by":"publisher","unstructured":"Hughes T et al (2022) Nov., First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies, Blood, 140(Supplement 1):6780\u20136781, https:\/\/doi.org\/10.1182\/blood-2022-170401","DOI":"10.1182\/blood-2022-170401"},{"key":"5906_CR23","doi-asserted-by":"publisher","unstructured":"Cortes JE et al (2021) Nov., A Phase 1b\/2 Study of Navtemadlin (KRT-232), a Murine Double Minute 2 Inhibitor, Combined with a BCR-ABL Tyrosine Kinase Inhibitor in Patients with Relapsed\/Refractory, TP53 WT, Ph\u2009+\u2009Chronic Myeloid Leukemia, Blood, 138(Supplement 1):2562\u20132562, https:\/\/doi.org\/10.1182\/blood-2021-145218","DOI":"10.1182\/blood-2021-145218"},{"key":"5906_CR24","doi-asserted-by":"publisher","unstructured":"Senapati J et al (2022) Nov., A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML), Blood, 140(Supplement 1):3880\u20133882, https:\/\/doi.org\/10.1182\/blood-2022-170773","DOI":"10.1182\/blood-2022-170773"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05906-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05906-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05906-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T01:05:40Z","timestamp":1730855140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05906-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["5906"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05906-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Spanish Medicines Agency (AEMPS) and the Ethics Committee of the Hospital Universitario Ram\u00f3n y Cajal (Madrid, Spain), with informed consent obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"L. Pe\u0301rez Lamas: Novartis; travel grants. Incyte; travel grants. V. Garcia-Gutierrez: Novartis; BMS; Incyte; Pfizer; travel grants, research funding, advisory board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}